ViPOR: a multi-targeted therapy for the treatment of R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 2:15 11 months ago 214 Далее Скачать
Reduced R-CHOP in favourable-prognosis DLBCL doesn't compromise outlook VJHemOnc – Video Journal of Hematology & HemOnc 4:40 6 years ago 733 Далее Скачать
Improving support services for patients with R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 1:05 2 years ago 132 Далее Скачать
How the treatment landscape of DLBCL is changing: R-CHOP vs pola-R-CHP VJHemOnc – Video Journal of Hematology & HemOnc 5:30 2 years ago 2 881 Далее Скачать
Acalabrutinib and AZD9150 combination for the treatment of R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 1:38 2 years ago 51 Далее Скачать
Long-term outcomes with tafasitamab plus lenalidomide for R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 1:31 3 years ago 372 Далее Скачать
The important role of bispecific antibodies in the future treatment of R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 1:54 2 years ago 105 Далее Скачать
What's New in the Approach to DLBCL Upfront and in the Relapsed Setting Beyond CAR T HMP Education 21:56 4 years ago 1 143 Далее Скачать
Impact of TMTV on PFS following glofitamab treatment in R/R DLBCL VJHemOnc – Video Journal of Hematology & HemOnc 2:21 10 months ago 121 Далее Скачать
Exploring available third-line treatment options for R/R DLBCL: CAR-T, bispecifics, ADCs & mAbs VJHemOnc – Video Journal of Hematology & HemOnc 2:49 1 year ago 125 Далее Скачать
What Are Common Side Effects of DLBCL Treatment? Patient Empowerment Network 1:31 2 years ago 174 Далее Скачать
